UnitedHealthUNH

Business Snapshot

• UnitedHealth Group Incorporated is a US-listed common stock (NYSE: UNH; CIK 731766), not an ETF, ADR, warrant, or unit.
• The supplied data does not include a business description or sector/industry classification, so this briefing focuses on the company’s reported financials and market data.

Financial Trends

• Revenue: Latest reported quarter (June 30, 2026) revenue was $112.032B, up $311M (+0.3%) from March 2026’s $111.721B and down $1.129B (-1.0%) from September 2025’s $113.161B. The December 2025 figure of $447.567B appears to be an annual period, not directly comparable with the quarterly figures; a clean four-quarter revenue trajectory cannot be calculated from this table.
• Margins and earnings: Operating margin improved from 3.81% in September 2025 to 4.24% in the December 2025 annual period and 8.05% in March 2026, then eased 0.92 percentage points to 7.13% in June. Net margin followed a similar pattern: 2.07% → 2.69% → 5.62% → 4.90%. Latest operating income of $7.991B and net income of $5.484B were down $999M (-11.1%) and $796M (-12.7%), respectively, from March. The December annual earnings and margins are not directly comparable with quarterly amounts.
• Free cash flow: Reported FCF was $18.402B in June, up $10.253B (+125.8%) from March’s $8.149B, up $2.487B (+15.6%) from September’s $15.915B, and up $2.327B (+14.5%) from the December figure of $16.075B. The March-to-June rebound is substantial; the December figure may reflect a different reporting basis, so period comparability should be checked.
• Balance sheet: From September 2025 to June 2026, cash increased $1.375B (+5.1%) to $28.585B, while long-term debt declined $2.898B (-4.0%) to $69.501B. Debt/equity improved from 0.71 to 0.66 over that span. Equity rose $2.944B (+2.9%) to $104.513B, though total assets fell $5.542B (-1.8%) and liabilities fell $5.678B (-2.7%).

Financial Health

• The latest quarter combines a strong reported FCF figure and improving debt/equity with softer sequential earnings: June operating income, net income, and margins all declined versus March.
• Cash of $28.585B provides liquidity, but current liabilities of $111.820B exceed current assets of $86.860B. The current ratio was 0.78 in June, down from 0.82 in September 2025; working capital worsened from -$20.459B to -$24.960B across those dates.
• Long-term debt has edged lower across the supplied balance-sheet periods, but the negative working-capital position remains a point to monitor. No valuation, guidance, or forward estimates are supplied.

Insider Activity

• The reported sentiment is Neutral (0) for July 1–September 29, 2026. It records 12 buy-coded transactions and no sells, but reports $0 total buys and net activity.
• The listed September 22 Form 4 entries show share amounts coded as buys at $0. Because no transaction value is reported, these entries do not establish open-market purchases or provide a meaningful dollar signal.
• Several filing links are listed without transaction details in the supplied data, so their activity cannot be assessed here.

Multi-Timeframe Technical Context

• Ultra-short (minutes): No intraday or minute-level candles/indicators are provided. The market is marked pre-market, so the supplied daily price and levels do not describe a live intraday setup.
• Short-term (hours to days): The supplied daily indicators show a weak setup with some oversold-bounce potential. RSI(14) is 26.86, below the conventional 30 threshold, while RSI(21) is 38.42. Price at $377.83 is below the 12-, 26-, and 50-day EMAs ($378.60, $385.31, $391.33) and below the 20- and 50-day SMAs ($384.14, $398.41). MACD is negative (-6.7115), though slightly above its signal (-6.838).
• Weeks to months: Price remains above the 200-day SMA of $355.70, but is below the shorter-term averages, leaving the longer-term picture mixed rather than confirmed as a recovery. The 200-bar daily summary reports a 17.07% change from its starting open of $322.75 to the latest close, but also a very wide high–low range of $255.965–$461.62. The latest volume (4.68M) is below its 20-day average (5.23M). ATR is $9.49, indicating notable daily price movement.

Bull / Bear Cases

• Short-term bull case: RSI(14) is oversold, MACD is marginally above its signal, and price is still above the 200-day SMA. A hold above the lower Bollinger Band near $363.31 followed by a reclaim of the 12-day EMA and 20-day SMA could support a relief bounce.
• Short-term bear case: Price is below the 12-, 26-, and 50-day EMAs and below the 20- and 50-day SMAs; MACD remains negative. A failure to hold the lower Bollinger Band would weaken the setup, with the 200-day SMA near $355.70 a further reference point.
• Long-term bull case: The supplied balance-sheet trend shows lower long-term debt and improved debt/equity, while June FCF rose sharply from March and remained above the September figure. Price is also above its 200-day SMA.
• Long-term bear case: June margins and earnings retreated from March, revenue was slightly lower than in September 2025, and working capital/current ratio remain weak and deteriorated versus September. The wide reported daily price range also signals substantial market uncertainty. The supplied information does not include a company outlook or comparable four-quarter revenue series.

Key Levels & Triggers

• Near-term resistance: $378.60 (12-day EMA), then $384.14 (20-day SMA/Bollinger middle), $385.31 (26-day EMA), and $391.33–$398.41 (50-day EMA/SMA).
• Near-term support: $363.31 (lower Bollinger Band), followed by $355.70 (200-day SMA). These are indicator references, not guaranteed support.
• Bullish technical trigger: A sustained move back above the 12-day EMA and 20-day SMA would improve the short-term picture; reclaiming the 50-day averages would provide a stronger recovery signal.
• Bearish technical trigger: A decisive break below the lower Bollinger Band, particularly if followed by a loss of the 200-day SMA, would increase downside risk.
• Fundamental trigger to watch: Whether margins and earnings stabilize after their March-to-June decline, and whether reported FCF strength persists. The supplied data contains no forward guidance or event calendar.